Vanda Pharmaceuticals settles Hetlioz LQ patent litigation with MSN
VNDA•Vanda Pharmaceuticals settled Hetlioz LQ patent litigation with MSN Pharmaceuticals and MSN Laboratories on Nov. 16, 2026. MSN received a license to market generic tasimelteon oral suspension in the U.S. starting in the first quarter of 2040, with earlier entry possible under specified conditions.




